Drug Approval | November 19, 2022
Eugia Pharma receives USFDA approval for Amphotericin B Liposome for Injection
The product is expected to be launched by Q4 FY23.
The product is expected to be launched by Q4 FY23.
The approval further strengthens the Potassium Chloride franchise for the company.
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.
The company is making its entry into the Hyderabad market through its unique asset-light business model
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
Value chain collaboration aims to foster a circular ecosystem and reduce the carbon footprint of single-use surgical instruments molded in Ixef PARA.
Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US
Subscribe To Our Newsletter & Stay Updated
